On January 27, Lockheed Martin's (LMT) shares closed at ~$503.70. Following the release of Q4 and FY2024 results and FY2025 outlook on January 28, 2025, the share price plunged ~$46. I now view Lockheed Martin's share price weakness as a buying opportunity and acquired an additional 50 shares @ $457.75 in one of the 'Core' [...]
After ~38 years of investing, I have lost count of my errors of omission and commission. Intuitive Surgical (ISRG) has to rank amongst one of my biggest errors! On October 20, 2021, I initiated a 30 share position in one of the 'Core' accounts within the FFJ Portfolio. I subsequently acquired another 30 shares on November [...]
High entry barriers fortify Union Pacific (UNP). My UNP exposure, however, is minimal with my only purchase being 200 shares @ $142.17 on March 9, 2020 while I was on a ski vacation in British Columbia; we were days from experiencing a 'shut down' of the North American economy because of the COVID pandemic. My [...]
Johnson & Johnson (JNJ) is virtually irrelevant to my investment strategy, and therefore, I rarely look at this investment. With the release of the Q4 and FY2024 financial results on January 22, 2025, I figure this is the opportunity to look at it more closely. Twice a year I disclose which companies are my [...]
With ~$11.6T in assets under management (AUM) following a record $641B of full year net inflows, including $281B in Q4 2024, I view BlackRock (BLK) as a great long-term investment. What I need to determine is whether BLK's valuation is sufficiently attractive to increase my exposure. I last reviewed BLK in my October 17, 2024 [...]
I have made my fair share of errors of commission and omission over the years! One of my errors of omission is not initiating a Cintas (CTAS) position when I looked at it in this November 10, 2017 post. On August 16, 2016, shortly after I retired, CTAS announced its intent to acquire G&K Services, [...]
Following the release of Q3 and YTD2024 results on August 26, 2024, I disclosed the purchase of 100 HEICO (HEI and HEI-a) Class A shares @ ~$189.47 in a 'Core' account within the FFJ Portfolio in my August 27 post. On October 28, I purchased an additional 100 Class A shares @ ~$195.58 through the [...]
I currently have insignificant PepsiCo, Inc. (PEP) exposure within a retirement account for which I do not disclose details. As evidence of how little interest I have in this company, I have not reviewed this holding since this July 12, 2022 post. I strongly suspect that world-class athletes rarely consume PEP products. People who lead [...]
In my September 28, 2024 How Stock Based Compensation Distorts Free Cash Flow post, I state that I have been giving more thought to how stock-based compensation (SBC) distorts Free Cash Flow (FCF). In subsequent posts that are accessible through The FFJ Archives, I look at a company's FCF using two methods. The first method [...]
I last reviewed Becton Dickinson (BDX) in this August 6, 2024 post at which time I thought the company was on the path to improved returns; BDX had recently released its Q3 and YTD2024 results and revised FY2024 guidance and announced its plan to acquire Edwards Lifesciences' Critical Care Product Group. On September 3, [...]